| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Prevention Studies Branch, Division of Cancer Prevention and Control [M. E. R., A. S., P. R. T.], and Epidemiology and Biostatistics Program, Division of Cancer Etiology [R. B. H., R. G. Z., J. F. F.], National Cancer Institute, Bethesda, Maryland 20892; and Information Management Services, Silver Spring, Maryland 20910 [L. L. K.]
The relation between serum vitamin A measurements made at baseline examination (19711975) and subsequent development of prostate cancer was examined in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study (19811984). The analytic cohort consisted of 2440 men 50 years of age or older who were followed for a median of 10 years. A total of 84 men developed prostate cancer. The mean level of serum vitamin A was significantly lower (P < 0.01) in prostate cancer cases than in noncases. Considered as a continuous variable or in quartiles, a statistically significant (P < 0.005 or P < 0.02, respectively) trend was observed for increased risk of prostate cancer with decreasing levels of serum vitamin A. Adjusted for age and race, men in the lowest quartile had a relative risk of 2.2 (95% confidence intervals, 1.1, 4.3) compared to those in the highest quartile. The elevated risk of prostate cancer associated with the lowest quartile of serum vitamin A levels did not attenuate with increasing time between blood drawing and diagnosis, suggesting that metabolic effects of early disease are an unlikely explanation of these results. The inverse association between serum vitamin A and prostate cancer incidence was independent of age at examination and several other possible confounding variables. This is the first prospective study of serum vitamin A and prostate cancer to include a large (84) number of cases.
1 The NHANES I Epidemiologic Follow-up Study has been developed and funded by these agencies: National Institute on Aging; National Center for Health Statistics; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases; National Institute of Mental Health; National Institute of Alcohol Abuse and Alcoholism; National Institute of Allergy and Infectious Disease; and National Institute of Neurological and Communicative Disorders and Stroke. The field work was conducted by Westat, Inc., under Contract 23380-2049.
2 To whom requests for reprints should be addressed, at National Cancer Institute, NIH, 9000 Rockville Pike, EPN 211, Bethesda, MD 20892.
Received 9/28/89.
Revised 1/ 9/90.
This article has been cited by other articles:
![]() |
T. J Key, P. N Appleby, N. E Allen, R. C Travis, A. W Roddam, M. Jenab, L. Egevad, A. Tjonneland, N. F Johnsen, K. Overvad, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study Am. J. Clinical Nutrition, September 1, 2007; 86(3): 672 - 681. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Trasino, E. H. Harrison, and T. T. Y. Wang Androgen Regulation of Aldehyde Dehydrogenase 1A3 (ALDH1A3) in the Androgen-Responsive Human Prostate Cancer Cell Line LNCaP Experimental Biology and Medicine, June 1, 2007; 232(6): 762 - 771. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-H. Tang, M.-J. Suh, R. Li, and L. J. Gudas Cell proliferation inhibition and alterations in retinol esterification induced by phytanic acid and docosahexaenoic acid J. Lipid Res., January 1, 2007; 48(1): 165 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kim, J. Lapointe, G. Kaygusuz, D. E. Ong, C. Li, M. van de Rijn, J. D. Brooks, and J. R. Pollack The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer Cancer Res., September 15, 2005; 65(18): 8118 - 8124. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mao, V. E. Reuter, C. Cordon-Cardo, G. Dalbagni, H. I. Scher, J. B. deKernion, Z.-F. Zhang, and J. Rao Decreased Retinoid X Receptor-{alpha} Protein Expression in Basal Cells Occurs in the Early Stage of Human Prostate Cancer Development Cancer Epidemiol. Biomarkers Prev., March 1, 2004; 13(3): 383 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Spitzweg, I. V. Scholz, E. R. Bergert, D. J. Tindall, C. Y. F. Young, B. Goke, and J. C. Morris Retinoic Acid-Induced Stimulation of Sodium Iodide Symporter Expression and Cytotoxicity of Radioiodine in Prostate Cancer Cells Endocrinology, August 1, 2003; 144(8): 3423 - 3432. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Huang, A. J. Alberg, E. P. Norkus, S. C. Hoffman, G. W. Comstock, and K. J. Helzlsouer Prospective Study of Antioxidant Micronutrients in the Blood and the Risk of Developing Prostate Cancer Am. J. Epidemiol., February 15, 2003; 157(4): 335 - 344. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huang, W. C. Powell, A. C. Khodavirdi, J. Wu, T. Makita, R. D. Cardiff, M. B. Cohen, H. M. Sucov, and P. Roy-Burman Prostatic Intraepithelial Neoplasia in Mice with Conditional Disruption of the Retinoid X Receptor{alpha} Allele in the Prostate Epithelium Cancer Res., August 15, 2002; 62(16): 4812 - 4819. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Ferrari, N. Stone, R. Stock, M. Bednar, I. Esseesse, H. Singh, Y. Baldwin, and J. Mandeli 13-cis Retinoic Acid and Complete Androgen Blockade in Advanced Hormone-Naive Prostate Cancer Patients: Report of a Phase II Randomized Study J. Clin. Oncol., January 15, 2002; 20(2): 538 - 544. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q.-Y. Lu, J.-C. Hung, D. Heber, V. L. W. Go, V. E. Reuter, C. Cordon-Cardo, H. I. Scher, J. R. Marshall, and Z.-F. Zhang Inverse Associations between Plasma Lycopene and Other Carotenoids and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 749 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lotan, X. C. Xu, M. Shalev, R. Lotan, R. Williams, T. M. Wheeler, T. C. Thompson, and D. Kadmon Differential Expression of Nuclear Retinoid Receptors in Normal and Malignant Prostates J. Clin. Oncol., January 1, 2000; 18(1): 116 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I. Graubard and E. L. Korn Analyzing Health Surveys for Cancer-Related Objectives J Natl Cancer Inst, June 16, 1999; 91(12): 1005 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pasquali, V. Rossi, D. Prezioso, V. Gentile, V. Colantuoni, T. Lotti, A. Bellastella, and A. A. Sinisi Changes in Tissue Transglutaminase Activity and Expression during Retinoic Acid-Induced Growth Arrest and Apoptosis in Primary Cultures of Human Epithelial Prostate Cells J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1463 - 1469. [Abstract] [Full Text] |
||||
![]() |
P. H. Gann, J. Ma, E. Giovannucci, W. Willett, F. M. Sacks, C. H. Hennekens, and M. J. Stampfer Lower Prostate Cancer Risk in Men with Elevated Plasma Lycopene Levels: Results of a Prospective Analysis Cancer Res., March 1, 1999; 59(6): 1225 - 1230. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |